➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
McKinsey
McKesson
Merck

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IVERMECTIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ivermectin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00127504 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed Universidad del Valle, Guatemala Phase 2 2003-07-01 The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
NCT00127504 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed University of Alabama at Birmingham Phase 2 2003-07-01 The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
NCT00127504 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed Centers for Disease Control and Prevention Phase 2 2003-07-01 The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
NCT00207753 Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections Completed Universidad del Valle, Guatemala N/A 2005-02-01 The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.
NCT00207753 Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections Completed Centers for Disease Control and Prevention N/A 2005-02-01 The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.
NCT00215280 Epidemiology and Control of Mansonella Perstans Infection in Uganda Completed Ministry of Health, Uganda N/A 2005-11-01 Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.
NCT00215280 Epidemiology and Control of Mansonella Perstans Infection in Uganda Completed DBL -Institute for Health Research and Development N/A 2005-11-01 Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ivermectin

Condition Name

Condition Name for Ivermectin
Intervention Trials
Covid19 25
Lymphatic Filariasis 15
COVID 14
Covid-19 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ivermectin
Intervention Trials
Filariasis 22
Elephantiasis 21
Elephantiasis, Filarial 20
Onchocerciasis 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ivermectin

Trials by Country

Trials by Country for Ivermectin
Location Trials
United States 63
France 15
Egypt 10
Ghana 6
Argentina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ivermectin
Location Trials
California 10
Florida 10
Texas 4
Tennessee 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ivermectin

Clinical Trial Phase

Clinical Trial Phase for Ivermectin
Clinical Trial Phase Trials
Phase 4 17
Phase 3 43
Phase 2/Phase 3 14
[disabled in preview] 81
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ivermectin
Clinical Trial Phase Trials
Not yet recruiting 55
Completed 43
Recruiting 39
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ivermectin

Sponsor Name

Sponsor Name for Ivermectin
Sponsor Trials
Washington University School of Medicine 11
London School of Hygiene and Tropical Medicine 10
Jennifer Keiser 5
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ivermectin
Sponsor Trials
Other 220
Industry 31
U.S. Fed 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Medtronic
Boehringer Ingelheim
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.